Search research articles
Contact Us
Filters
Showing results (51-60 of 389) with videos related to
Page
of 39
Sort By:
Pharmacology, Biochemistry, and Behavior
|
May 20, 2008
GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?
Jayne E Bailey, David J Nutt
Depression and Anxiety
|
November 23, 2006
Role of GABA in anxiety and depression
Allan V Kalueff, David J Nutt
Lancet (London, England)
|
March 18, 2014
Deaths from "legal highs": a problem of definitions
Leslie A King, David J Nutt,
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 22, 2012
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
David S Baldwin, David J Nutt
Nature Medicine
|
May 25, 2021
Putting the MD back into MDMA
David J Nutt, Harriet de Wit
European Addiction Research
|
September 25, 2024
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Ioanna A Vamvakopoulou, David J Nutt
The Lancet. Psychiatry
|
August 29, 2016
Question-based Drug Development for psilocybin - Authors' reply
Robin L Carhart-Harris, David J Nutt
Current Opinion in Pharmacology
|
January 22, 2005
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder
Kevin C F Fone, David J Nutt
Journal of Studies on Alcohol and Drugs
|
March 22, 2024
A Perspective on Psychedelics as Treatments for Addictions
David J Nutt, Celia Morgan, Sukhpreet Klaire
International Journal of Tryptophan Research : IJTR
|
November 16, 2011
Tryptophan research in panic disorder
Eduard Maron, Jakov Shlik, David J Nutt
Page
of 39
Search research articles
Search
Showing results (51-60 of 389) with videos related to
Sort By:
Page
of 39
Pharmacology, Biochemistry, and Behavior
|
May 20, 2008
GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?
Jayne E Bailey, David J Nutt
Depression and Anxiety
|
November 23, 2006
Role of GABA in anxiety and depression
Allan V Kalueff, David J Nutt
Lancet (London, England)
|
March 18, 2014
Deaths from "legal highs": a problem of definitions
Leslie A King, David J Nutt,
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 22, 2012
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
David S Baldwin, David J Nutt
Nature Medicine
|
May 25, 2021
Putting the MD back into MDMA
David J Nutt, Harriet de Wit
European Addiction Research
|
September 25, 2024
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Ioanna A Vamvakopoulou, David J Nutt
The Lancet. Psychiatry
|
August 29, 2016
Question-based Drug Development for psilocybin - Authors' reply
Robin L Carhart-Harris, David J Nutt
Current Opinion in Pharmacology
|
January 22, 2005
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder
Kevin C F Fone, David J Nutt
Journal of Studies on Alcohol and Drugs
|
March 22, 2024
A Perspective on Psychedelics as Treatments for Addictions
David J Nutt, Celia Morgan, Sukhpreet Klaire
International Journal of Tryptophan Research : IJTR
|
November 16, 2011
Tryptophan research in panic disorder
Eduard Maron, Jakov Shlik, David J Nutt
Page
of 39